CD274 and renal cell carcinoma: Thereafter, five other immune checkpoint-targeted therapies have been approved, all directed against PD-1 or PD-L1, for the treatment of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and a number of other tumor types, in monotherapy and combinatorial regiments.